Stock Information
Ligand Pharmaceuticals Inc (LGND)
Ticker Symbol: LGND
Exchange: NASDAQ
Sector: Pharmaceuticals
Market Cap: $4,633.12 mil
Piotroski score: 7
PE Ratio: 36.1191
EPS (TTM): 5.8832
Revenue (TTM): $12.97 M
Dividend Yield: N/A%
ROE: 13.86%
Latest News
-
Citigroup Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $282
Wed, Apr 15, 2026 4:08 PM
-
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI in FSGS
Wed, Apr 15, 2026 9:44 AM
-
Ligand Pharmaceuticals shares are trading higher after the company's partner Travere Therapeutics received FDA approval for a drug to treat kidney disease. Also, HC Wainwright & Co maintained its Buy rating on the stock and raised its price target from $239 to $243.
Tue, Apr 14, 2026 10:59 AM
-
HC Wainwright & Co. Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $243
Tue, Apr 14, 2026 10:56 AM
-
Ligand Pharmaceuticals Partner Travere Therapeutics Wins FDA Approval For First Drug Treating Rare Kidney Disease
Tue, Apr 14, 2026 7:07 AM
Key Financials
Financial data not available
